Telehealth companies push GLP-1s beyond approved use
Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 report from Bloomberg. About 93% of GLP-1 ads from telehealth companies focused on thinness and downplayed risks, according to research from Boulder-based University of Colorado […]
Will NVO’s U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of $199 per month for new self-pay patients in the United States, through March 31, 2026. Wegovy’s label includes cardiovascular, HFpEF, liver, and osteoarthritis indications, while Ozempic remains the […]
Eli Lilly 1st pharma company to reach $1 trillion market cap
Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants. Eli Lilly’s shares peaked Nov. 21, giving the pharmaceutical company market capitalization above $1 trillion before slightly dipping to $950 billion, according to The Wall Street […]
Readout of Phase 3 Semaglutide Trials Marks Critical Moment in Alzheimer’s Research and Suggests Potential for Combination Therapies
Data provides new insights into targeting the diverse pathobiology of Alzheimer’s disease, an approach spearheaded by the ADDF NEW YORK, Nov. 24, 2025 /PRNewswire/ — Today, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials of semaglutide, an oral GLP-1…
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials – The Wall Street Journal
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials The Wall Street JournalView Full Coverage on Google News
Women who give up weight-loss jabs for pregnancy can suffer harmful weight gain
When women taking weight loss jabs stop their use because of pregnancy, the rebound weight gain brings health risks for their babies. Women who paused the injections before or shortly after conceiving were more likely to gain excess weight in pregnancy, a study has found. This made them more likely to develop diabetes or high […]
New fat jab warning as pregnancy risks revealed, even after stopping use – from ‘premature birth to extra weight gain’
FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such as Wegovy or Mounjaro, but stopped just before pregnancy or in the first trimester were at higher risk of complications. Research by the Mass General Brigham Hospital in the USA found they…
Ozempic Pill Flops in Major Trials for Alzheimer’s
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease’s progression compared to a placebo.
The complicated relationship between GLP-1s and pregnancy
A new study sheds light on the risks and benefits of taking GLP-1 weight-loss drugs before having a baby.
People who stop using Mounjaro tend to regain weight and lose other health benefits, says study
Improvements such as reduced ‘bad’ cholesterol and lower blood pressure go into reverse upon stopping weight-loss jabsPeople who stop using the weight-loss jab Mounjaro not only tend to regain weight, but experience a reversal in other health improvements too, research suggests.Mounjaro, which contains the active ingredient tirzepatide, has become a popular medication for weight loss, with studies suggesting that it can help people lose an average of 20% of their body weight after 72 weeks of treatment. Continue reading…